Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 480-310-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 12 February 2007 to 11 April 2007
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted under GLP conditions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- Days 1 and 2 animls of group 4 dosed 40 mg/kg/day instead of 100 mg/kg/day.Max time btwn form and dose of test substance >4 hours by 50 minutes on Day 3,stability in vehicle indicated to be > 96 hours.Temp lower than min.No dev. adversely affected results
- GLP compliance:
- yes
- Limit test:
- no
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material (as cited in study report): MTDID 6675
- Substance type: Clear colourless liquid
- Physical state: Liquid
- Analytical purity: Formulation tested is 30.0% active ingredient in water
- Purity test date: 12/20/2005
- Lot/batch no.: 140499-8/25
- Expiration date of the lot/batch:02 July 2008
- Storage condition of test material: Refrigerated (2-8 degrees C) in the dark
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: Approximately 7 weeks.
- Weight at study initiation: Males (Means of Groups 1-4): 253-256 g, Females (Means of Groups 1-4): 181-190 g.
- Fasting period before study:
- Housing: Group housing of 5 animals per sex in Macrolon cages (MIV type, height 18 cm; during overnight activity monitoring individual housing in MIII type; height 15 cm) with sterilized sawdust as bedding material (Litalabo, S.P.P.S., Argenteuil, France) and paper as cage-enrichment (Enviro-dri, Wm. Lilico & Son (Wonham Mili Ltd), Surry, United Kingdom). No cage-enrichment was provided during overnight activity monitoring. Certificates of analysis are examined and then retained in the NOTOX archives.
- Diet (e.g. ad libitum): Pelleted rodent diet (SM R/M-Z from SSNIFF Spezialdiaten GmbH, Soest, Germany) ad libitum.
- Water (e.g. ad libitum): Tap water ad libitum.
- Acclimation period: At least 5 days before the start of treatment.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17.9 to 22.6 degrees Celsius
- Humidity (%): 36-86%
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 14 March 2007 To: 11 April 2007
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: Groups 1-4 (0, 10, 30, 100 mg test article/kg/day respectively)
- Amount of vehicle (if gavage): Total dose is 10 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analytical method used was validated under NOTOX project 481578.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily, 7 days per week, with a maximum of 4 hours difference between the earliest and latest dose.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Basis:
actual ingested
- No. of animals per sex per dose:
- 5 males and 5 females per dose.
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Doses were based on the results of an 8-day range finding study.
- Rationale for animal assignment (if not random): Random - Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Once before treatment and weekly thereafter.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: At least once daily
BODY WEIGHT: Yes
- Time schedule for examinations: On days 1, 8, 15, 22, and 28.
FOOD CONSUMPTION AND COMPOUND INTAKE):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Collected at end of treatment before necropsy.
- Anaesthetic used for blood collection: Yes, under iso-flurane anaesthesia (Abbott Laboratories LTd. Zwolle, The Netherlands)
- Animals fasted: Yes
- How many animals: All animals.
- Parameters checked in table: WBC, differntial leucocyte count, RBC, reticulocytes, RBC distribution width, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular heamoglobin concentration, platelets, prothrombin time, and activated partial thromboplastin time were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Collected at end of treatment before necropsy.
- Animals fasted: Yes
- How many animals: All animals
- Parameters checked in table alanine aminotransfterase, alkaline phosphatase, total protein, albumin, total bilirubin, urea, creatinine, glucose, cholesterol, sodium, potassium, chloride, calcium, and inorganic phosphate were examined.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During week 4 of treatment
- Dose groups that were examined: All dose groups were examined
- Battery of functions tested: Hearing, pupilary reflex, static righting reflex and grip strength. - Sacrifice and pathology:
- GROSS PATHOLOGY
HISTOPATHOLOGY
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no clinical signs of toxicity noted.
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality occured during the study period.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weights and body weight gain of treated animals remained in the same range as controls over the 4-week study period.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption before or after allowance for body weight was similar between treated and control animals.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Slightly decreased haemoglobin and haematocrit level was noted in males at 100 mg/kg/day. Minor statistically significant increase of activated partial thromboplastin time (APTT) noted in females at 30 mg/kg/day were considered to have arisen by chance. No dose response distribution was noted and all values were within the physiological range. Therefore, this finding was considered not to represent a change of biological significance. No changes in haematological parameters were noted in males at 0, 10, and 30 mg/kg/day and females at 0, 10, 100 mg/kg/day.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Increased levels of alkaline phosphatase (ALP), urea and inorganic phosphate were noted in males at 100 mg/kg/day. Glucose and potassium levels were increased in males at 20 and 100 mg/kg/day. Decreased level of bilirubin was noted in all males at 10, 30, and 100 mg/kg/day. Slight increased creatinine level and decreased calcium levels were noted in females at 100 mg/kg/day. No changes in clinical biochemical parameters were noted in females at 10 and 30 mg/kg/day.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Hearing ability, pupillary reflex, static righting reflex and grip strength were normal in all animals. The variation in motor activity did not indicate a relation with treatment.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Absolute and relative liver weight was increased in males at 30 and 100 mg/kg/day. In addition relative liver weight was increased in males at 10 mg/kg/day. Slight increase in absolute and relative adrenal weight was noted in females at 100 mg/kg/day. This statistically significant change was slight and all values were within the physiological range. No clear dose response was noted. The finding was therefore considered to have no toxicological significance. Not changes in absolute organ weight were noted in males at 10 mg/kg/day. No changes in absolute and relative oragan weight were noted in females at 10 and 30 mg/kg/day.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- At macroscopic examination the liver was found to be enlarged in two males at 100 mg/kg/day. No macroscopic abnormalities were noted among males at 10 and 30 mg/kg/day and control females.
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Diffuse midzonal/centrilobular hyperthrophy of hepatocytes was noted at minor degrees in all males at 10 and 30 mg/kg/day and at slight or moderate degree in all males at 100 mg/kg/day. Diffuse follicular hypertrophy/hyperplasia in thyroid glands was seen at increased incidence and severity up to slight in males at 100 mg/kg/day. All other microscopic findings were within the range of background pathology encountered in Wistar rats of this age and strain and occurred at similar incidences and severity in both control and treated rats.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- No neoplastic histopathological findings were noted.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- The No Observed Adverse Effect Level (NOAEL) for the test article in this study was 10 mg/kg for males and 100 mg/kg for females.
- Effect level:
- ca. 10 - ca. 100 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- gross pathology
- haematology
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The No Observed Adverse Effect Level (NOAEL) for the test article in this study was 10 mg/kg for males and 100 mg/kg for females.
- Executive summary:
The potential toxicity of the test article (liquid, supplied at 29.9 ± 0.1% in water, lot 140499-19/10) was evaluated in male and female Wistar rats when administered by daily oral gavage for 28 days following OECD Guideline No. 407. The test material was diluted in Milli-U water to the appropriate concentrations and stock solution strength and specific gravity were included in calculations. The test article was administered by oral gavage to 5 animals/sex/group at 0 (Milli-U water), 10, 30 and 100 mg/kg daily for 28 days. The following parameters were evaluated: clinical signs daily; functional observation tests in week 4; body weight and food consumption weekly; clinical pathology and macroscopy at termination; organ weights and histopathology on a selection of tissues. There were no test material related findings for any dose group in clinical appearance, functional observations, body weight and food consumption. The following changes in serum levels were noted in males treated at 100 mg/kg: increased alkaline phosphatase, increased glucose (also in males at 30 mg/kg), increased urea, increased inorganic phosphate, increased potassium (also in males at 30 mg/kg), decreased hemoglobin, and decreased hematocrit. Findings in females were limited to increased creatinine and decreased calcium in the 100 mg/kg dose group. Liver weight was increased in males at 30 and 100 mg/kg which was supported by an increased incidence and severity of hepatocellular hypertrophy/hyperplasia. Increased incidence and severity of thyroid follicular hypertrophy up to 100 mg/kg in males was considered an adaptive change to the increases in liver. The increase in liver weight was considered adverse. In conclusion, the No Observed Adverse Effect Level (NOAEL) for the test article in this study was 10 mg/kg for males and 100 mg/kg for females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
